* Eton Pharmaceuticals Inc ETON.OQ ETON.O is expected
to show
a fall in quarterly revenue when it reports results on August
10.
* The Deer Park Illinois-based company is expected to
report a
11.5% decrease in revenue to $6.509 million from $7.36 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for Eton
Pharmaceuticals Inc
is for a loss of 9 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Eton
Pharmaceuticals Inc is $9, above its last closing price
of $2.61.
This summary was machine generated August 9 at 02:04 GMT. All
figures in US dollars unless otherwise stated